Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 May 11;S1286-4579(20)30082-4.
doi: 10.1016/j.micinf.2020.05.004. Online ahead of print.

From SARS-CoV to SARS-CoV-2: Safety and Broad-Spectrum Are Important for Coronavirus Vaccine Development

Affiliations
Free PMC article

From SARS-CoV to SARS-CoV-2: Safety and Broad-Spectrum Are Important for Coronavirus Vaccine Development

Cuiqing Ma et al. Microbes Infect. .
Free PMC article

Abstract

The global pandemic of COVID-19 caused by SARS-CoV-2 (also known as 2019-nCoV and HCoV-19) has posed serious threats to public health and economic stability worldwide, thus calling for development of vaccines against SARS-CoV-2 and other emerging and reemerging coronaviruses. Since SARS-CoV-2 and SARS-CoV have high similarity of their genomic sequences and share the same cellular receptor (ACE2), it is essential to learn the lessons and experiences from the development of SARS-CoV vaccines for the development of SARS-CoV-2 vaccines. In this review, we summarized the current knowledge on the advantages and disadvantages of the SARS-CoV vaccine candidates and prospected the strategies for the development of safe, effective and broad-spectrum coronavirus vaccines for prevention of infection by currently circulating SARS-CoV-2 and other emerging and reemerging coronaviruses that may cause future epidemics or pandemics.

Keywords: 2019-nCoV; Cross-protection; HCoV-19; SARS-CoV; SARS-CoV-2; Vaccine.

Conflict of interest statement

Declaration of Competing Interest The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Distribution of clinical-phage vaccine candidates for COVID-19 and their lead developers.
Figure 2
Figure 2
Schematic of spike protein structure of SARS-CoV-2 and SARS-CoV. SP, signal peptide; NTD: N-terminal domain; RBD, receptor-binding domain; RBM, receptor-binding motif; FP, fusion peptide; HR, heptad repeat; TM, transmembrane domain; CP, cytoplasm domain.
Figure 3
Figure 3
Specific amino acid variations among the S proteins of SARS-CoV and SARS-CoV-2. Letters in magenta and yellow represent different amino acids in the corresponding sequences of SARS-CoV and SARS-CoV-2, respectively. A. Sequence alignment of SARS-CoV and SARS-CoV-2 RBDs. The red number indicates the core amino acids in RBD when it binds to receptor ACE2. The green frame is the amino acid sequence of RBM. B. Sequence alignment of SARS-CoV and SARS-CoV-2 HR1. The red frame is the location where the variable amino acid residues between SARS-CoV and SARS-CoV-2 HR1.

Similar articles

See all similar articles

References

    1. Zhu N., Zhang D., Wang W., Li X., Yang B., Song J. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727–733. - PMC - PubMed
    1. Zhang N., Wang L., Deng X., Liang R., Su M., He C. Recent advances in the detection of respiratory virus infection in humans. J Med Virol. 2020;92:408–417. - PMC - PubMed
    1. Jiang S., Shi Z.-L. The first disease X is caused by a highly transmissible acute respiratory syndrome coronavirus. Virol Sin. 2020 doi: 10.1007/s12250-020-00206-5. [online ahead of print] - DOI
    1. Yu F., Du L., Ojcius D.M., Pan C., Jiang S. Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan, China. Microbes Infect. 2020;22:74–79. - PMC - PubMed
    1. WHO. Coronavirus. Available at https://www.who.int/health-topics/coronavirus. Accessed 20 January 2020.

LinkOut - more resources

Feedback